Inventiva S.A. (IVA)
NASDAQ: IVA · IEX Real-Time Price · USD
3.240
+0.080 (2.53%)
May 1, 2024, 3:52 PM EDT - Market closed
Inventiva Revenue
In the year 2023, Inventiva had annual revenue of $25.74M with 28.59% growth.
Revenue (ttm)
$25.74M
Revenue Growth
+28.59%
P/S Ratio
6.59
Revenue / Employee
$214,472
Employees
120
Market Cap
169.68M USD
Revenue Chart
* The company reports in EUR currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 25.74M | 5.72M | 28.59% |
Dec 31, 2022 | 20.01M | 10.35M | 107.19% |
Dec 31, 2021 | 9.66M | 3.24M | 50.51% |
Dec 31, 2020 | 6.42M | -6.27M | -49.41% |
Dec 31, 2019 | 12.69M | 4.20M | 49.58% |
Dec 31, 2018 | 8.48M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Inogen | 315.66M |
InfuSystem Holdings | 125.79M |
Harvard Bioscience | 112.25M |
Butterfly Network | 65.90M |
Capricor Therapeutics | 25.18M |
Orchestra BioMed Holdings | 2.76M |
IVA News
- 4 weeks ago - Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F - GlobeNewsWire
- 4 weeks ago - Inventiva announces the nomination of Andre Turenne as Director - GlobeNewsWire
- 5 weeks ago - Inventiva reports its 2023 full-year results - GlobeNewsWire
- 5 weeks ago - Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results - GlobeNewsWire
- 6 weeks ago - Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D - GlobeNewsWire
- 7 weeks ago - Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D - GlobeNewsWire
- 7 weeks ago - Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed - GlobeNewsWire
- 2 months ago - Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3 - GlobeNewsWire